Agios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of “Buy” by Brokerages

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has received an average recommendation of “Buy” from the fourteen research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $80.22.

Several brokerages have issued reports on AGIO. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Royal Bank of Canada boosted their target price on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group boosted their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd.

In related news, insider Steven L. Hoerter sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $74.83, for a total transaction of $1,870,750.00. Following the sale, the insider now directly owns 25,000 shares in the company, valued at approximately $1,870,750. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene acquired 851,154 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were bought at an average price of $67.00 per share, for a total transaction of $57,027,318.00. Following the completion of the purchase, the insider now owns 1,374,599 shares in the company, valued at approximately $92,098,133. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 187,114 shares of company stock worth $14,109,545. 5.43% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of AGIO. Schwab Charles Investment Management Inc. grew its position in Agios Pharmaceuticals by 16.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 96,866 shares of the biopharmaceutical company’s stock worth $4,984,000 after buying an additional 13,539 shares in the last quarter. Principal Financial Group Inc. grew its position in Agios Pharmaceuticals by 33.8% during the second quarter. Principal Financial Group Inc. now owns 7,083 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 1,789 shares in the last quarter. Wells Fargo & Company MN grew its position in Agios Pharmaceuticals by 138.4% during the second quarter. Wells Fargo & Company MN now owns 95,547 shares of the biopharmaceutical company’s stock worth $4,915,000 after buying an additional 55,463 shares in the last quarter. Alliancebernstein L.P. grew its position in Agios Pharmaceuticals by 16.3% during the second quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 3,050 shares in the last quarter. Finally, Teachers Advisors LLC grew its position in Agios Pharmaceuticals by 54.4% during the second quarter. Teachers Advisors LLC now owns 46,733 shares of the biopharmaceutical company’s stock worth $2,404,000 after buying an additional 16,475 shares in the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $3.07 on Friday, hitting $71.19. The company’s stock had a trading volume of 129,268 shares, compared to its average volume of 843,209. The company has a market capitalization of $3,620.00, a price-to-earnings ratio of -11.44 and a beta of 2.12. Agios Pharmaceuticals has a 52-week low of $45.11 and a 52-week high of $82.96.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/09/agios-pharmaceuticals-inc-agio-given-consensus-recommendation-of-buy-by-brokerages.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply